Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. Pharmasset's research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. In January 2012, Pharmasset was acquired by Gilead Sciences. The valuation of Pharmasset was $11.2 billion.
Pharmasset has filed 8 patents.
Prodrugs, HIV/AIDS, Virology, Antivirals, Animal viral diseases
Prodrugs, HIV/AIDS, Virology, Antivirals, Animal viral diseases
Latest Pharmasset News
Jul 20, 2022
07/20/2022 | 04:44am EDT Message : *Required fields 20 July, 2022 - Resolution Therapeutics Limited ("Resolution"), a biopharmaceutical company developing macrophage cell therapies to treat advanced liver disease, today announced the appointment of Dr. Bill Symonds as a Non-Executive Director of the Company. Bill brings experience in drug development and building biotech businesses gained over an accomplished and successful 30-year career in the industry. "It is a huge pleasure to welcome Bill to our Board of Directors. He is an accomplished executive with expertise in bringing transformative therapies to market and building successful development organisations. Having developed and commercialised Solvadi® and Harvoni®, the leading HCV treatments, Bill brings a deep understanding of drug development in advanced liver disease," said Edward Hodgkin, Partner of Syncona Investment Management Limited who serves as Chairman and CEO of Resolution. "I look forward to working with Bill as Resolution grows into an industry-leading company with a pipeline of macrophage cell therapies designed to treat patients with liver cirrhosis." "I'm delighted to be joining Resolution at this important stage in the company's growth," added Bill Symonds. "The Company is the leader in the development of macrophage cell therapy for advanced liver disease, and I look forward to working with the experienced team to bring badly-needed treatments to patients with the potential to avoid the need for liver transplantation." Dr. Symonds currently serves as the Chief Executive Officer of Altavant Sciences and Enzyvant Sciences, both Sumitovant wholly-owned subsidiaries. Previously, Dr. Symonds was a member of the founding management team at Roivant Sciences, Inc., where he served as Chief Development Officer. Earlier in his career, Dr. Symonds held senior positions at a number of pharmaceutical companies, including Pharmasset, Inc. where he led the development of hepatitis C virus infection medicine Solvadi®.Pharmasset was later acquired by Gilead where he continued to serve as VP Liver Disease Therapeutic Area and progressed Solvadi® as well as Harvoni® through to FDA approval. Prior to Pharmasset, Dr. Symonds worked at GSK on numerous medicines for HIV infection. Dr. Symonds received his Doctor of Pharmacy from Campbell University and completed a fellowship in clinical pharmacokinetics at the Clinical Pharmacokinetics Laboratory at Millard Fillmore Hospital in Buffalo, New York. He has authored or co-authored over 35 clinical articles and is named on nine patents related to the composition of matter and methods of use of drugs for hepatitis C infection. - Ends -
Pharmasset Frequently Asked Questions (FAQ)
When was Pharmasset founded?
Pharmasset was founded in 1998.
Where is Pharmasset's headquarters?
Pharmasset's headquarters is located at 303 College Road E, Princeton.
What is Pharmasset's latest funding round?
Pharmasset's latest funding round is Acq - P2P.
How much did Pharmasset raise?
Pharmasset raised a total of $51.31M.
Who are the investors of Pharmasset?
Investors of Pharmasset include Gilead Sciences, MPM Capital, TVM Capital, Lumira Ventures, CDIB BioScience Venture Management and 4 more.
Who are Pharmasset's competitors?
Competitors of Pharmasset include Sierra Oncology, Blue Heron Biotech, GenVec, Cebix, Jennerex Biotherapeutics and 7 more.
Compare Pharmasset to Competitors
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
Vector Biolabs specializes in gene delivery systems within the biotechnology sector. The company offers a range of services including the production of recombinant adenovirus and adeno-associated virus (AAV) vectors, as well as custom services for vector design, cloning, packaging, amplification, and purification. It is based in Philadelphia, Pennsylvania.
DNAtrix operates as a biotechnology company developing virus-driven immunotherapies to treat cancer. It develops modified viruses for the treatment of the most aggressive forms of cancer. The company was founded in 2005 and is based in Carlsbad, California.
Agrisoma BioSciences is a company focused on sustainable biofuel production in the renewable energy sector. The company's main product is Carinata, a non-food crop that is used to produce low greenhouse gas fuels and provide protein for animal nutrition. It is based in Gatineau, Quebec.
Targeson is a biotechnology company that develops, manufactures, and markets ultrasound contrast agent technologies for pre-clinical molecular imaging in animal models. Targeson is also developing this technology for site-specific diagnosis and therapy in humans. The company has engineered a versatile microparticle platform that may be used as both a contrast agent and, in a slightly modified form, a drug or gene delivery agent. Targeson manufactures and sells the Targestarline of contrast agents for ultrasound-based molecular and functional imaging in animal models of disease. Targeson's agents can be readily targeted to the molecular signature of many diseases, and can be used to detect pathophysiology on the molecular level. The company's intellectual property aims to enable the agents to bind with high efficiency to the intended molecular targets. In addition, the company is investigating therapeutic technology for simultaneous imaging and delivery, which aims to enable the user to verify that the therapeutic compound has been delivered to the intended site.
OrphageniX is a drug development company aiming to develop therapeutics for genetic diseases using advancements in "Gene Editing" technologies. OrpageniX will focus on the low volume, high margin specialty pharmaceutical niche area of "Orphan Diseases" which are protected under the Orphan Drug Act (ODA). Per the company, the OrphageniX technology can be used for diagnostics and research tools. Gene Editing uses the cell's innate repair mechanisms to repair mutations that result in genetic diseases. According to OrphaageniX, it is similar to gene therapy but avoids the risks associated with a viral vector. It works like anti-sense and RNAi, but is more efficient and permanent within the repaired cell because it changes the gene itself and not the transient message. The company states that it has major collaborations with Yale Medical School, Albert Einstein Medical Center and the University of Washington.